As shown in Table 6, the three predictors of the increasing LOS in the recovery room, in decreasing order of importance, were: a longer duration of the procedure. older age of the patient. the antiemetic drug administered (the use of granisetron or dolasetron versus ondansetron drug).
No dosing adjustment is necessary for any of the three antiemetic agents in patients with renal impairment. In patients with hepatic impairment, the clearance of ondan-setron is reduced and the half-life is increased significantly. In patients with mild, moderate, and severe hepatic impairment, the elimination half-life is 9.1 hours, 9.2 hours, and 20.6 hours, respectively. [...]
Table 1 presents a summary of the pharmacokinetic and pharmacodynamic properties of ondansetron, granisetron canadian, and dolasetron. Ondansetron Ondansetron tablet was the first selective serotonin receptor antagonist to be marketed. It is administered both orally and parenterally. Following an oral dose, it is absorbed by the gastrointestinal (GI) tract and undergoes extensive hepatic metabolism, primarily [...]
A retrospective chart review was performed for 300 randomly selected adults undergoing inpatient and outpatient procedures from March 2003 to February 2004. Initially, 100 patients were in the dolasetron group, 99 were in the ondan-setron group, and 101 were in the generic granisetron group. As a result of having received combination therapy at the outset, [...]
INTRODUCTION At Winthrop University Hospital, we set out to determine the most cost-effective agent among three 5-hydroxy-tryptamine-3 (5-HT3) receptor antagonists—drug ondansetron (Zofran generic, GlaxoSmithKline), generic granisetron (Kytril generic, Roche), and dolasetron (Anzemet®, Aventis)—in preventing postoperative nausea and vomiting (PONV). PONV is a major complication for patients undergoing surgical procedures.
